Dosing of Antimycotic Treatment in Sepsis–Induced Liver Dysfunction by Functional Liver Testing with LiMAx®
Background. Sepsis-treatment is one of the major challenges in our time. Especially fungal infections play an important role in patient’s morbidity and mortality. In patients with septic shock, liver function is often significantly impaired and therefore also hepatic drug metabolism is altered. Case...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Series: | Case Reports in Critical Care |
| Online Access: | http://dx.doi.org/10.1155/2019/5362514 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850230845919461376 |
|---|---|
| author | Carmen Kirchner Jasmin Sibai Elke Schwier Dietrich Henzler Claas Eickmeyer Günther Winde Thomas Köhler |
| author_facet | Carmen Kirchner Jasmin Sibai Elke Schwier Dietrich Henzler Claas Eickmeyer Günther Winde Thomas Köhler |
| author_sort | Carmen Kirchner |
| collection | DOAJ |
| description | Background. Sepsis-treatment is one of the major challenges in our time. Especially fungal infections play an important role in patient’s morbidity and mortality. In patients with septic shock, liver function is often significantly impaired and therefore also hepatic drug metabolism is altered. Case Presentation. We report about a 56-year-old man suffering from invasive fungal infection with multiorgan failure, after complicated medical history due to symptomatic infrarenal aortic aneurysm. On the first postoperative day, a CT scan was undertaken due to massive back pain showing renal infarction on both sides. As qualitative and quantitative renal function was impaired, hemodialysis was started immediately. Subsequently, the patient developed a compartment syndrome of the left leg and underwent fasciotomy. On admission day 7, the patient presented with hematochezia leading to colonoscopy. During this procedure, an ischemic colitis was observed. As conservative treatment failed, the patient underwent Hartmann’s procedure due to progredient ischemia followed by a worsening of the clinical status due to sepsis. The patient suffered from an invasive fungal infection with Candida spp. and Aspergillus spp. Systemic antifungal treatment was initiated. Although azoles are considered first-line treatment in these cases we chose the echinocandin caspofungin for its presumed lower impact on liver function compared to azoles like voriconazole or Amphothericin B. However, caspofungin is also metabolised in the liver and can cause hepatotoxic effects. Therefore we measured metabolic liver function capacity using LiMAx®and adapted the patient’s dose of caspofungin to the evaluated liver function capacity to achieve an effective and liver-protective level of the active drug. After complicated medical history with 15 weeks of hospital stay, the patient was discharged in general good condition. Conclusions. To our knowledge, this is the first report that relates antimycotic drug dosing to a functional liver test. We provide a new approach for sepsis treatment considering liver function capacity to optimize dosage of hepatically metabolised drugs with potential hepatotoxic effects. |
| format | Article |
| id | doaj-art-0b5cdc66fdc24304ae16f2f7d346d5cb |
| institution | OA Journals |
| issn | 2090-6420 2090-6439 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Critical Care |
| spelling | doaj-art-0b5cdc66fdc24304ae16f2f7d346d5cb2025-08-20T02:03:43ZengWileyCase Reports in Critical Care2090-64202090-64392019-01-01201910.1155/2019/53625145362514Dosing of Antimycotic Treatment in Sepsis–Induced Liver Dysfunction by Functional Liver Testing with LiMAx®Carmen Kirchner0Jasmin Sibai1Elke Schwier2Dietrich Henzler3Claas Eickmeyer4Günther Winde5Thomas Köhler6Department of General and Visceral Surgery, Thoracic Surgery and Proctology, Ruhr University Bochum, Klinikum Herford, Herford, GermanyDepartment of General and Visceral Surgery, Thoracic Surgery and Proctology, Ruhr University Bochum, Klinikum Herford, Herford, GermanyDepartment of Anesthesiology, Surgical Intensive Care, Emergency and Pain Medicine, Ruhr University Bochum, Klinikum Herford, Herford, GermanyDepartment of Anesthesiology, Surgical Intensive Care, Emergency and Pain Medicine, Ruhr University Bochum, Klinikum Herford, Herford, GermanyDepartment of Anesthesiology, Surgical Intensive Care, Emergency and Pain Medicine, Ruhr University Bochum, Klinikum Herford, Herford, GermanyDepartment of General and Visceral Surgery, Thoracic Surgery and Proctology, Ruhr University Bochum, Klinikum Herford, Herford, GermanyDepartment of Anesthesiology, Surgical Intensive Care, Emergency and Pain Medicine, Ruhr University Bochum, Klinikum Herford, Herford, GermanyBackground. Sepsis-treatment is one of the major challenges in our time. Especially fungal infections play an important role in patient’s morbidity and mortality. In patients with septic shock, liver function is often significantly impaired and therefore also hepatic drug metabolism is altered. Case Presentation. We report about a 56-year-old man suffering from invasive fungal infection with multiorgan failure, after complicated medical history due to symptomatic infrarenal aortic aneurysm. On the first postoperative day, a CT scan was undertaken due to massive back pain showing renal infarction on both sides. As qualitative and quantitative renal function was impaired, hemodialysis was started immediately. Subsequently, the patient developed a compartment syndrome of the left leg and underwent fasciotomy. On admission day 7, the patient presented with hematochezia leading to colonoscopy. During this procedure, an ischemic colitis was observed. As conservative treatment failed, the patient underwent Hartmann’s procedure due to progredient ischemia followed by a worsening of the clinical status due to sepsis. The patient suffered from an invasive fungal infection with Candida spp. and Aspergillus spp. Systemic antifungal treatment was initiated. Although azoles are considered first-line treatment in these cases we chose the echinocandin caspofungin for its presumed lower impact on liver function compared to azoles like voriconazole or Amphothericin B. However, caspofungin is also metabolised in the liver and can cause hepatotoxic effects. Therefore we measured metabolic liver function capacity using LiMAx®and adapted the patient’s dose of caspofungin to the evaluated liver function capacity to achieve an effective and liver-protective level of the active drug. After complicated medical history with 15 weeks of hospital stay, the patient was discharged in general good condition. Conclusions. To our knowledge, this is the first report that relates antimycotic drug dosing to a functional liver test. We provide a new approach for sepsis treatment considering liver function capacity to optimize dosage of hepatically metabolised drugs with potential hepatotoxic effects.http://dx.doi.org/10.1155/2019/5362514 |
| spellingShingle | Carmen Kirchner Jasmin Sibai Elke Schwier Dietrich Henzler Claas Eickmeyer Günther Winde Thomas Köhler Dosing of Antimycotic Treatment in Sepsis–Induced Liver Dysfunction by Functional Liver Testing with LiMAx® Case Reports in Critical Care |
| title | Dosing of Antimycotic Treatment in Sepsis–Induced Liver Dysfunction by Functional Liver Testing with LiMAx® |
| title_full | Dosing of Antimycotic Treatment in Sepsis–Induced Liver Dysfunction by Functional Liver Testing with LiMAx® |
| title_fullStr | Dosing of Antimycotic Treatment in Sepsis–Induced Liver Dysfunction by Functional Liver Testing with LiMAx® |
| title_full_unstemmed | Dosing of Antimycotic Treatment in Sepsis–Induced Liver Dysfunction by Functional Liver Testing with LiMAx® |
| title_short | Dosing of Antimycotic Treatment in Sepsis–Induced Liver Dysfunction by Functional Liver Testing with LiMAx® |
| title_sort | dosing of antimycotic treatment in sepsis induced liver dysfunction by functional liver testing with limax r |
| url | http://dx.doi.org/10.1155/2019/5362514 |
| work_keys_str_mv | AT carmenkirchner dosingofantimycotictreatmentinsepsisinducedliverdysfunctionbyfunctionallivertestingwithlimax AT jasminsibai dosingofantimycotictreatmentinsepsisinducedliverdysfunctionbyfunctionallivertestingwithlimax AT elkeschwier dosingofantimycotictreatmentinsepsisinducedliverdysfunctionbyfunctionallivertestingwithlimax AT dietrichhenzler dosingofantimycotictreatmentinsepsisinducedliverdysfunctionbyfunctionallivertestingwithlimax AT claaseickmeyer dosingofantimycotictreatmentinsepsisinducedliverdysfunctionbyfunctionallivertestingwithlimax AT guntherwinde dosingofantimycotictreatmentinsepsisinducedliverdysfunctionbyfunctionallivertestingwithlimax AT thomaskohler dosingofantimycotictreatmentinsepsisinducedliverdysfunctionbyfunctionallivertestingwithlimax |